Generic Name and Formulations:
Idarucizumab 2.5g/50mL; soln for IV inj; preservative-free; contains sorbitol.
Boehringer Ingelheim Pharmaceuticals
Indications for PRAXBIND:
Reversal of the anticoagulant effects of dabigatran in emergency surgery/urgent procedures and in life-threatening or uncontrolled bleeding.
For IV use only. Administer 5g (2 vials) as 2 consecutive infusions or as bolus injection of both vials consecutively via syringe. Other additional dose: see Warnings/Precautions.
Thromboembolic risk; consider resuming anticoagulant therapy as soon as medically appropriate; can initiate dabigatran 24hrs after Praxbind administration. In patients having a reappearance of bleeding with elevated coagulation parameters or those requiring a second emergency surgery/urgent procedure and have elevated coagulation parameters, consider repeat administration of Praxbind 5g dose. Discontinue immediately if hypersensitivity reactions occur and treat appropriately. Hereditary fructose intolerance. Pregnancy. Nursing mothers.
Humanized monoclonal antibody fragment.
Headache, constipation, nausea; hypersensitivity reactions.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response
- Higher-Dose Immunoglobulin Replacement Therapy in Chronic Lymphocytic Leukemia
- Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers
- Finding Clinical Trials in Cancer
- Adding Nintedanib Did Not Improve Survival in Lung Cancer Subtype
- The Identification of a Potential Early Plasma Biomarker for Kidney Cancer
- Pembrolizumab Plus Chemotherapy Extended Survival Longer Than Chemotherapy Alone: Study
- Combining Chemotherapy With Checkpoint Inhibitors Extends Overall Survival in ES-SCLC
- In a Head-to-Head Battle, Brigatinib Appears to Best Crizotinib